Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling

PURPOSE: To overcome cytochrome P450 2D6 (CYP2D6) mediated tamoxifen resistance in postmenopausal early breast cancer, CYP2D6 phenotype-adjusted tamoxifen dosing in patients with impaired CYP2D6 metabolism and/or the application of endoxifen, the most potent tamoxifen metabolite, are alternative tre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dickschen, Kristin, Eissing, Thomas, Mürdter, Thomas, Schwab, Matthias, Willmann, Stefan, Hempel, Georg
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058004/
https://ncbi.nlm.nih.gov/pubmed/24936398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-3-285
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados